Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al
Case Number:
1:20-cv-00706
Court:
Nature of Suit:
Judge:
Firms
- Armstrong Teasdale
- Bennett Bricklin
- Calcagni & Kanefsky
- Chiesa Shahinian
- Crowell & Moring
- Dechert LLP
- DLA Piper
- Dorsey & Whitney
- Duane Morris
- Goodwin Procter
- Kang Haggerty
- Kasowitz Benson
- Kishner Miller
- Morgan Lewis
- Morgan Melhuish
- Obermayer Rebmann
- Phillips Nizer
- Sheppard Mullin
- Whiteford Taylor
- Wilson Sonsini
Companies
- Cardinal Health Inc.
- Cencora Inc.
- Cerovene Inc.
- Medisca Pharmaceutique Inc.
- Teva Pharmaceutical Industries Ltd.
- Vyera Pharmaceuticals LLC
Government Agencies
Sectors & Industries:
-
June 28, 2024
Shkreli Asks High Court To Toss $64M Disgorgement Order
Former pharmaceutical executive Martin Shkreli, who gained notoriety for hiking the price of HIV/AIDS medication before serving more than four years in prison for securities fraud, is asking the U.S. Supreme Court to toss a disgorgement order requiring him to pay $64 million for monopolistic price-gouging.
-
February 27, 2023
FTC Pushes To Hold Shkreli In Contempt
The Federal Trade Commission continued urging a New York federal court to hold convicted "pharma bro" Martin Shkreli in contempt for failing to comply with document requests in an investigation into accusations he violated an order banning him from working in the pharmaceutical industry.
-
February 10, 2023
Shkreli Says His New Co. Doesn't Violate FTC's Pharma Ban
Convicted "Pharma Bro" Martin Shkreli opposed the Federal Trade Commission's contempt motion accusing him of failing to comply with an order banning him from working in the pharmaceutical industry, arguing that his new company Druglike Inc. is a software business, not a pharmaceutical company.
-
January 20, 2023
FTC Wants Shkreli Held In Contempt Over Stonewalling
The Federal Trade Commission asked a New York federal judge on Friday to hold "Pharma Bro" Martin Shkreli in contempt for failing to turn over documents it said were essential to the agency's investigation into whether he violated an order banning him from working in the pharmaceutical industry.
-
June 10, 2022
States Get $853K In Pared Down Shkreli Antitrust Case Fees
A New York federal judge signed off Friday on $853,440.80 in attorney fees for four of the states that successfully sued "pharma bro" Martin Shkreli for an anti-competitive scheme safeguarding a 40-fold price increase for a lifesaving drug, a significant reduction on the more than $2 million initially sought.
-
April 26, 2022
States In Shkreli FTC Trial Told To Redo $2.2M Atty Fee Ask
Disgraced former pharmaceutical executive Martin Shkreli is on the hook for the attorney fees from states that joined in his antitrust trial, but they cannot get the $2.2 million they requested and must revise their calculation, a New York federal judge ruled Tuesday.
-
April 25, 2022
Shkreli Poses 'Serious Risk' Without Pharma Ban, Judge Says
A New York federal judge denied Martin Shkreli's request to lift his lifetime ban from participating in the pharmaceutical industry while he appeals it, saying Monday that "there is a serious risk" he will reengage in anti-competitive conduct that will harm patients.
-
April 12, 2022
Duane Morris Says Shkreli Owes It $2M In Bid To Drop Client
Duane Morris LLP is seeking to withdraw as Martin Shkreli's counsel in an antitrust case against the disgraced pharmaceutical executive, telling a New York federal court that the firm hasn't been paid since October and is owed more than $2 million, and that Shkreli is out of money.
-
March 18, 2022
Shkreli Can't Press Pause On $64M Antitrust Judgment
Disgraced former pharmaceutical executive Martin Shkreli can't put off paying a $64.6 million antitrust judgment against him while he fights it in a higher court, a New York federal judge has ruled.
-
March 15, 2022
States Fight Shkreli's Bid To Pause Monetary Penalty
Seven states that helped the Federal Trade Commission win an antitrust case against "pharma bro" Martin Shkreli are lining up to implore a New York federal judge not to allow him to put off paying the $64.6 million judgment against him while he appeals.